HopeStage
Back to all studies
CompletedNCT01875822

Curcumin C-3 Complex for Schizophrenia and Related Conditions

About this titleRead the official source — NCT01875822
Interventional studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
San JuanSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2009
Recruitment status
Completed
Enrollment listed in the registry
17
Sponsor
Woodbury, Michel, M.D.
Sponsor type
Unknown or unclear
Study type
Other
Intervention type
Dietary supplement
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT01875822
Official title
Show the full official title

Open Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

San Juan, Puerto Rico · United States

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Woodbury, Michel, M.D.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies